December 22, 2020

Vaxchora Indication Expanded to Include Children

December 22, 2020 – The U.S. FDA has approved an expanded indication for Vaxchora® (cholera vaccine, live) oral suspension, manufactured by Emergent Travel Health. The vaccine, which
December 21, 2020

Ebanga Becomes Second FDA-Approved Ebola Drug

December 21, 2020 – The U.S. FDA has approved EbangaTM (ansuvimab), manufactured by Ridgeback Pharmaceuticals, to treat Zaire ebolavirus infection (Ebola) in adults and children. Ebanga is
December 21, 2020

Xeomin Receives Expanded Indication

December 21, 2020 – The U.S. FDA has approved an expanded chronic sialorrhea indication for Xeomin® (incobotulinumtoxinA), manufactured by Merz Pharmaceuticals. Previously approved to
December 21, 2020

Indications Expanded for Three Cystic Fibrosis Drugs

December 21, 2020 – The U.S. FDA has approved expanded indications for three medications from Vertex Pharmaceuticals that are indicated to treat cystic fibrosis (CF), with patients selected